Deyev, S.M.; Oroujeni, M.; Garousi, J.; Gräslund, T.; Li, R.; Rosly, A.H.B.; Orlova, A.; Konovalova, E.; Schulga, A.; Vorobyeva, A.;
et al. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion. Int. J. Mol. Sci. 2024, 25, 4246.
https://doi.org/10.3390/ijms25084246
AMA Style
Deyev SM, Oroujeni M, Garousi J, Gräslund T, Li R, Rosly AHB, Orlova A, Konovalova E, Schulga A, Vorobyeva A,
et al. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion. International Journal of Molecular Sciences. 2024; 25(8):4246.
https://doi.org/10.3390/ijms25084246
Chicago/Turabian Style
Deyev, Sergey M., Maryam Oroujeni, Javad Garousi, Torbjörn Gräslund, Ruonan Li, Alia Hani Binti Rosly, Anna Orlova, Elena Konovalova, Alexey Schulga, Anzhelika Vorobyeva,
and et al. 2024. "Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion" International Journal of Molecular Sciences 25, no. 8: 4246.
https://doi.org/10.3390/ijms25084246
APA Style
Deyev, S. M., Oroujeni, M., Garousi, J., Gräslund, T., Li, R., Rosly, A. H. B., Orlova, A., Konovalova, E., Schulga, A., Vorobyeva, A., & Tolmachev, V.
(2024). Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion. International Journal of Molecular Sciences, 25(8), 4246.
https://doi.org/10.3390/ijms25084246